MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that Marksans Pharma Limited''s newly acquired manufacturing facility has successfully undergone inspection from German health authorities. MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Prior Intimation Of Board Meeting
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 ,inter alia, to consider and approve To consider and approve the unaudited financial results of the Company (both standalone and consolidated) for the quarter and half year ended September 30, 2023 MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received intimation from our RTA, M/S Big shares services Private Limited today regarding issuance of duplicate share certificate of the Company as per the details attached MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Credit Rating
We wish to inform that CARE Ratings Limited has assigned credit ratings to the banking facilities of Marksans Pharma Limited. MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed certificate under regulation 74(5) of SEBI Depositories regulation for quarter ended September 30, 2023 received from Bigshare Services Private Limited(RTA). MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received one request from a shareholder for issue of duplicate share certificate in lieu of lost/misplaced original share certificate Marksans receives USFDA approval for Esomeprazole Magnesium capsules
Shares of the company were down 0.86 per cent on the BSE MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Final approval from US FDA for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium delayed-release capsule USP, 20 mg (OTC). MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
In terms of Company''s code of conduct and SEBI (PIT) regulations, the trading window will remain closed from Sunday, 1st October, 2023 til 48hrs after the declaration of financial results for quarter ended September 30, 2023. MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received one request from shareholder for issue of duplicate share certificate in lieu of lost/misplaced share certificate. Our RTA has received the completed documents for issuing duplicate share certificate on August 30, 2023